Xeris Biopharma Holdings, Inc. revenue by segment XERS

Annual Quarterly

Xeris Biopharma Holdings, Inc. splits its revenue into 5 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Recorlev at $139.3 million, 48% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line	FY 2026 Sep 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021
Revenue	368	292	203	164	110	50
Recorlev	—	139 +116.7% share 47.7%	64 +117.5% share 31.7%	30 +297.7% share 18.0%	7 share 6.7%	—
Gvoke	—	94 +13.6% share 32.2%	83 share 40.8%	—	53 +35.0% share 47.6%	39 share 78.5%
Keveyis	—	48 -3.8% share 16.3%	50 -12.8% share 24.4%	57 +15.1% share 34.6%	49 +375.8% share 44.7%	10 share 20.9%
Royalty Contract And Other Revenue	—	9 +37.4% share 3.0%	6 -39.0% share 3.2%	11 +971.1% share 6.4%	1 +217.7% share 0.9%	0 share 0.6%
Product Other	—	2 share 0.7%	—	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: XERS (Nasdaq)
Fiscal year ends: December 31
Headquarters: Chicago, IL
SEC filer status: Large accelerated filer
SEC CIK: 1867096

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.